United Therapeutics Corporation UTHR

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

The Morning Bull - US Market Morning Update Thursday, Oct, 1 2026 US stock futures are pointing slightly higher this morning, with the S&P 500 mini contract up about 0.2% and the Nasdaq-100 mini edging 0.1% stronger, as investors weigh fresh signals on inflation and global growth. The key focus is the Federal Reserve's preferred inflation gauge, the PCE index, with headline inflation expected at 3.7% and core at 3.3%. That means the cost of living is still running above the Fed's 2% goal. At...

Why Liquidia Stock Crashed 57% on Wednesday’s Patent Ruling Against YutrepiaLiquidia (LQDA:NASDAQ) stock crashed 57% on Wednesday, September 30, after a Delaware court ruled that Yutrepia infringes two valid claims of United Therapeutics’ ‘327 patent. Those claims cover treating pulmonary hypertension with interstitial lung disease (PH-ILD) using inhaled treprostinil, and the court struck down the rest.

United Therapeutics Corporation (UTHR:NASDAQ) shares jumped about 13% on Wednesday, September 30 (closing at $542), after a federal court ruled that rival Liquidia’s lung drug infringes its treprostinil patent. Liquidia (LQDA:NASDAQ) fell nearly 50% on the same ruling, wiping out about $3.

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled that competitor Liquidia Corporation infringed patent claims covering United Therapeutics' inhaled treprostinil treatments.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 30, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.

Healthcare stocks declined late Wednesday afternoon with the NYSE Healthcare Index and the State Str

Liquidia CEO Roger Jeffs said the company disagrees with the court’s decision and will “pursue all available appellate options.”

Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%.

District Court ruled that two of the six claims asserted against Liquidia are valid and infringedParties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding

Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics Corporation (NASDAQ:UTHR) on September 24, 2026, with a Sell rating and a $321 price target. The firm argues that shares trade above their historical valuation range while the core franchise shrinks, and that the market underestimates how hard the idiopathic pulmonary fibrosis (IPF) launch will […]

Earlier this week, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag, alongside a US$2.00 billion share repurchase authorization. At the same time, United Therapeutics is pushing ahead with long-horizon xenotransplantation efforts, including a xenokidney registration trial that management aims to...

United Therapeutics (UTHR) moved into focus after Goldman Sachs started coverage with a Sell rating, sending the stock down 4%, a meaningful single session move for a relatively steady biotech stock. Goldman’s call lands after a choppy stretch for United Therapeutics, with the share price down 7.76% over 30 days and 12.75% over 90 days, even though the 1-year total shareholder return of 9.89% and 3-year total shareholder return of 110.50% point to longer term momentum that appears...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of the stock with a Sell rating.